The Director of the San Raffaele-Telethon Institute for Gene Therapy Luigi Naldini reflects on what a recent Nature study reveals and about the future of in vivo gene transfer “Our study provides an ...

(a) Schematic of the in vivo CAR-T cell therapy process; (b) Clinically validated delivery platforms including LNP-based systems and viral vectors; (c) Emerging future directions for durable and ...

ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular therapy in multiple myeloma by reducing manufacturing, treatment delays, and ...